CEO David Jenkins Buys 9,489 Shares of Catheter Precision’s New Preferred Stock Amid 18‑Year‑Old Decline—A Quiet Bet on Future Growth

Insider Buying in a Volatile Health‑Tech Stock

Catheter Precision Inc. (CATH) is experiencing a quiet yet significant influx of insider capital. On February 12, 2026, Chairman and CEO David Jenkins purchased 2,491.29 shares of newly issued Series J Preferred Stock, followed shortly by an additional 6,998.20 shares in a separate transaction. Both purchases were executed at a price of $1.70, effectively matching the current market price and reflecting a neutral sentiment from social media chatter. While the company’s share price has slumped 18.66 % month‑to‑date and 75.15 % year‑to‑date, these insider transactions suggest a level of confidence that may reassure skeptical investors.

What This Means for the Bottom Line

The timing of Jenkins’ purchases aligns with Catheter Precision’s recent institutional financing announcement—an $36.5 million arrangement aimed at bolstering research and market expansion. By acquiring preferred shares, Jenkins signals an endorsement of the company’s capital structure and future growth prospects. For investors, this insider buying could serve as a contrarian cue in an otherwise depressed equity. However, the company’s negative earnings and a price‑to‑earnings ratio of –0.05 highlight that profitability remains a distant goal. The preferred stock, which is non‑exercisable until shareholder approval, may also be viewed as a strategic hedge against dilution while providing potential dividend benefits if the company’s cash flow improves.

Jenkins A: A Pattern of Commitment

Jenkins’ transaction history reveals a consistent pattern of buying, particularly of warrants and common stock. In December 2025, he executed two purchases of Series M Common Stock Purchase Warrants, each for 170,000 shares, and accumulated 34,579 shares of common stock in early December. Earlier that year, he also purchased a substantial block of options—500,000 shares—underscoring a long‑term stake in the firm. His activity has been primarily buy‑side, with a few sell‑side trades of Series X Convertible Preferred Stock that cleared to zero holdings. This disciplined buying behavior signals a belief in Catheter Precision’s long‑term trajectory, even as short‑term volatility persists.

Investor Takeaway

For seasoned investors, Jenkins’ recent preferred‑stock purchases reinforce the notion that the company’s top executive believes in its strategic plan and financing structure. The timing—just after a major funding round—may hint at an upcoming conversion event or dividend that could enhance shareholder value. However, the stock’s steep decline and negative earnings caution that the company is still navigating early‑stage growth pains. Monitoring future insider trades, especially any conversion of the Series J Preferred Stock, will be key to assessing whether this insider confidence translates into tangible market gains.